Voyager Therapeutics, Inc. (VYGR) is a publicly traded company in the Unknown sector. Across all available filings, 31 corporate insiders have executed 167 transactions totaling $118.2M, demonstrating a bullish sentiment with $69.4M in net insider flow. The most recent transaction on Feb 24, 2026 involved a sale of 4,174 shares valued at $15.7K.
No significant insider buying has been recorded for VYGR in the recent period.
No significant insider selling has been recorded for VYGR in the recent period.
Based on recent SEC filings, insider sentiment for VYGR is bullish with an Insider Alignment Score of 79/100 and a net flow of $69.4M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Voyager Therapeutics, Inc. (VYGR) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 31 insiders are actively trading VYGR stock, having executed 167 transactions in the past 90 days. The most active insider is Biosciences Inc Neurocrine (Executive), who has made 2 transactions totaling $89.0M.
Get notified when executives and directors at VYGR file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 24, 2026 | Alfred Carter Todd | Chief Scientific Officer | Sale | 4,174 | $3.76 | $15.7K | |
| Feb 24, 2026 | D. Jorgensen Nathan | Chief Financial Officer | Sale | 4,668 | $3.77 | $17.6K | C-Suite |
| Feb 24, 2026 | Sandrock Alfred | Executive | Sale | 14,197 | $3.79 | $53.8K | |
| Feb 24, 2026 | Swartz Robin | COO & CBO | Sale | 6,458 | $3.77 | $24.3K | C-Suite |
| Jan 6, 2026 | L. Shiferman Gregory | SVP and General Counsel | Award | 100,000 | $N/A | $0 | |
| Oct 3, 2025 | D. Jorgensen Nathan | Executive | Sale | 7,666 | $4.78 | $36.6K | |
| Aug 18, 2025 | Ferguson Toby | Executive | Sale | 19,000 | $3.73 | $70.9K | |
| Apr 2, 2024 | Sandrock Alfred | Executive | Sale | 12,115 | $9.86 | $119.5K | |
| Apr 2, 2024 | Swartz Robin | Executive | Sale | 1,357 | $9.88 | $13.4K | |
| Apr 1, 2024 | Ferguson Toby | Executive | Award | 105,000 | $N/A | $0 | |
| Feb 21, 2024 | Alfred Carter Todd | Executive | Sale | 3,365 | $7.47 | $25.1K | |
| Feb 21, 2024 | P. Pfreundschuh Peter | Executive | Sale | 3,764 | $7.46 | $28.1K | |
| Feb 21, 2024 | Sandrock Alfred | Executive | Sale | 13,033 | $7.46 | $97.2K | |
| Feb 21, 2024 | Swartz Robin | Executive | Sale | 3,966 | $7.45 | $29.5K | |
| Feb 20, 2024 | Alfred Carter Todd | Executive | Sale | 602 | $7.68 | $4.6K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 9 | $93.8M | 78.9% |
Sale(S) | 96 | $24.4M | 20.5% |
Exercise(M) | 10 | $763.9K | 0.6% |
Award(A) | 39 | $9.1K | 0.0% |
Other(J) | 9 | $0 | 0.0% |
Conversion(C) | 4 | $0 | 0.0% |
Insiders at Voyager Therapeutics, Inc. are accumulating shares at an accelerated pace. With 31 insiders making 167 transactions totaling $93.8M in purchases versus $24.4M in sales, the net buying activity of $69.4M signals strong executive confidence. Biosciences Inc Neurocrine (Executive) leads the buying activity with $89.0M in transactions across all time.